Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Five Prime Therapeutics Inc (NASDAQ:FPRX)

Delayed Data
As of May 25
 -0.61 / -1.38%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. Five Prime Therapeutics was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.

Contact Information

Five Prime Therapeutics, Inc.
Two Corporate Drive
South San Francisco California 94080-7047
P:(415) 365-5600
Investor Relations:
(415) 365-5737



Other institutional45.11%
Mutual fund holders35.33%
Individual stakeholders20.60%

Top Executives

Lewis T. WilliamsChairman, President & Chief Executive Officer
Marc L. BelskyChief Financial Officer & Senior Vice President
Aron M. KnickerbockerDirector, Chief Business Officer & Executive VP
Francis Willard SarenaSecretary, Executive VP & General Counsel
Robert Steven SikorskiSenior Vice President-Global Clinical Development